Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLGN NASDAQ:GUTS NASDAQ:NVNO NASDAQ:TELA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$1.82+0.1%$1.79$1.31▼$5.45$23.14M1.3337,727 shs32,124 shsGUTSFractyl Health$1.79+9.1%$1.82$0.87▼$4.70$80.32M1.58371,078 shs419,756 shsNVNOenVVeno Medical$5.25+23.0%$3.96$2.03▼$6.13$74.88M0.93114,662 shs636,203 shsTELATELA Bio$1.98-0.5%$1.67$0.86▼$4.78$78.71M0.9203,990 shs80,528 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies+0.08%+29.18%+16.76%-24.74%-63.72%GUTSFractyl Health+9.15%+17.76%-8.21%+46.72%-62.08%NVNOenVVeno Medical+22.95%+21.53%+22.38%+114.29%-11.76%TELATELA Bio-0.50%-4.35%+32.00%+107.07%-57.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLGNCollPlant Biotechnologies2.4038 of 5 stars3.73.00.00.02.60.00.6GUTSFractyl Health2.4282 of 5 stars3.53.00.00.02.60.00.0NVNOenVVeno Medical0.503 of 5 stars0.02.00.00.02.70.80.6TELATELA Bio2.9864 of 5 stars3.44.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLGNCollPlant Biotechnologies 3.33Buy$11.50531.38% UpsideGUTSFractyl Health 3.00Buy$11.00514.53% UpsideNVNOenVVeno Medical 0.00N/AN/AN/ATELATELA Bio 2.75Moderate Buy$7.25266.16% UpsideCurrent Analyst Ratings BreakdownLatest CLGN, TELA, GUTS, and NVNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLGNCollPlant Biotechnologies$510K45.43N/AN/A$1.18 per share1.54GUTSFractyl Health$90K974.16N/AN/A$0.59 per share3.03NVNOenVVeno MedicalN/AN/AN/AN/A$2.40 per shareN/ATELATELA Bio$69.30M1.13N/AN/A$0.72 per share2.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLGNCollPlant Biotechnologies-$16.61M-$1.22N/AN/AN/A-560.92%-87.33%-65.31%8/19/2025 (Estimated)GUTSFractyl Health-$68.69M-$1.85N/AN/AN/A-73,864.52%-228.66%-76.74%8/13/2025 (Estimated)NVNOenVVeno Medical-$21.82M-$1.18N/AN/AN/AN/A-51.32%-48.23%7/30/2025 (Estimated)TELATELA Bio-$37.84M-$1.41N/AN/AN/A-61.00%-402.45%-62.73%8/11/2025 (Estimated)Latest CLGN, TELA, GUTS, and NVNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025GUTSFractyl Health-$0.37N/AN/AN/AN/AN/A8/11/2025Q2 2025TELATELA Bio-$0.18N/AN/AN/A$20.67 millionN/A7/30/2025N/ANVNOenVVeno Medical-$0.28N/AN/AN/AN/AN/A6/4/2025Q1 2025CLGNCollPlant Biotechnologies-$0.37-$0.13+$0.24-$0.13$9.76 million$2.06 million5/13/2025Q1 2025GUTSFractyl Health-$0.49-$0.49N/A-$0.49N/AN/A5/8/2025Q1 2025TELATELA Bio-$0.21-$0.25-$0.04-$0.25$17.35 million$18.52 million4/30/2025Q1 2025NVNOenVVeno MedicalN/A-$0.22N/A-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/AGUTSFractyl HealthN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLGNCollPlant BiotechnologiesN/A4.484.23GUTSFractyl Health4.612.502.50NVNOenVVeno MedicalN/A23.7723.77TELATELA Bio2.284.223.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLGNCollPlant Biotechnologies21.69%GUTSFractyl HealthN/ANVNOenVVeno Medical34.71%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipCLGNCollPlant Biotechnologies9.60%GUTSFractyl HealthN/ANVNOenVVeno Medical16.00%TELATELA Bio4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLGNCollPlant Biotechnologies7012.72 million11.50 millionOptionableGUTSFractyl Health10248.98 millionN/AN/ANVNOenVVeno Medical3017.54 million14.73 millionOptionableTELATELA Bio12039.56 million37.70 millionOptionableCLGN, TELA, GUTS, and NVNO HeadlinesRecent News About These CompaniesTELA Bio (NASDAQ:TELA) Shares Down 5.4% - Here's What HappenedJuly 8, 2025 | marketbeat.comBreakeven On The Horizon For TELA Bio, Inc. (NASDAQ:TELA)July 3, 2025 | finance.yahoo.comTELA Bio Welcomes Jim Hagen with Strategic Equity GrantJune 9, 2025 | msn.comTELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 7, 2025 | finanznachrichten.deTELA Bio, Inc. Grants Inducement Equity Awards to New Senior Vice President Jim HagenJune 6, 2025 | quiverquant.comQTELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comTELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia RepairJune 4, 2025 | tmcnet.comTELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia RepairJune 3, 2025 | globenewswire.comTELA Bio Names Jeffrey Blizard as President to Drive Strategic GrowthJune 3, 2025 | msn.comTELA Bio Appoints Jeffrey Blizard as President to Drive Growth and InnovationJune 2, 2025 | quiverquant.comQTELA Bio Appoints Jeffrey Blizard as PresidentJune 2, 2025 | globenewswire.comTELA Bio to Present at the 2025 Jefferies Global Healthcare ConferenceMay 25, 2025 | msn.comTELA Bio to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 22, 2025 | globenewswire.comPiper Sandler Sticks to Their Hold Rating for TELA Bio (TELA)May 22, 2025 | theglobeandmail.comTELA Bio Announces Inducement Grants to New Hires with 4-Year Vesting PlanMay 12, 2025 | msn.comTELA Bio Reports Q1 2025 Growth and Product ExpansionMay 12, 2025 | msn.comTELA Bio, Inc. (TELA) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comEarnings call transcript: Tela Bio Q1 2025 revenue miss, stock rises 9%May 10, 2025 | uk.investing.comTELA Bio Reports First Quarter 2025 Financial ResultsMay 10, 2025 | finance.yahoo.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2025 | globenewswire.comTELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLGN, TELA, GUTS, and NVNO Company DescriptionsCollPlant Biotechnologies NASDAQ:CLGN$1.82 +0.00 (+0.08%) Closing price 07/17/2025 03:58 PM EasternExtended Trading$1.82 +0.00 (+0.20%) As of 07/17/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.Fractyl Health NASDAQ:GUTS$1.79 +0.15 (+9.15%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$1.80 +0.01 (+0.56%) As of 07/17/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.enVVeno Medical NASDAQ:NVNO$5.25 +0.98 (+22.95%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$5.38 +0.13 (+2.48%) As of 07/17/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. TELA Bio NASDAQ:TELA$1.98 -0.01 (-0.50%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$2.04 +0.06 (+3.23%) As of 07/17/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
